QQ客服 官方微博 反馈留言

	Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting
	Zhao, Jiangning ; Xu, Zhenshu ; Liu, Delong ; Lu, Quanyi ; Lu QY(鹿全意) ; Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting
	2012-08-23
关键词	B-CELL LYMPHOMA CHRONIC LYMPHOCYTIC-LEUKEMIA NON-HODGKINS-LYMPHOMA CHEMOTHERAPY PLUS RITUXIMAB RANDOMIZED CONTROLLED-TRIAL CHOP-LIKE CHEMOTHERAPY MULTICENTER PHASE-II ELDERLY-PATIENTS AGGRESSIVE LYMPHOMA THERAPY
英文摘要	Indolent lymphoma (IL), the second most common lymphoma, remains incurable with chemotherapy alone. While R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) remains the standard frontline regimen for diffuse Large B-cell lymphoma, the optimal chemotherapy regimen for frontline therapy of advanced IL remains uncertain. FCR (fludarabine, cyclophosphamide, rituximab) has been shown to be better than fludarabine alone and fludarabine plus cyclophosphamide for IL. In FOLL05 trial, R-CHOP was compared with R-CVP (cyclophosphamide, vincristine, prednisone) and R-FM (fludarabine, mitoxantrone). The study showed that R-CHOP appears to have the best risk-benefit ratio for IL. The StiL NHL1 trial showed that BR (bendamustine, rituximab) has longer progression free survival and is better tolerated than R-CHOP. Long-term complications with secondary malignancies between the two regimens appear to be comparable. In this review, new combination regimens reported at 2012 ASCO annual meeting were evaluated for frontline and salvage therapy of indolent lymphoma.
语种	英语
出版者	BIOMED CENTRAL LTD
内容类型	期刊论文
源URL	[http://dx.doi.org/10.1186/1475-2867-12-38]
专题	医学院－已发表论文
推荐引用方式 GB/T 7714	Zhao, Jiangning,Xu, Zhenshu,Liu, Delong,et al. Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting[J],2012.
APA	Zhao, Jiangning,Xu, Zhenshu,Liu, Delong,Lu, Quanyi,鹿全意,&Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting.(2012).Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting..
MLA	Zhao, Jiangning,et al."Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting".(2012).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。